MT-21 is an Apoptosis inducer and adenine nucleotide translocase inhibitor. MT-21 induces Apoptosis by activating JNK via the Krs/MST protein. MT-21 activates caspase-3 via caspase-9. MT-21 induces the release of cytochrome c. MT-21 can be used in the research of tumors.

BRL 55834 is an orally and potent potassium channel activator. BRL 55834 exhibits great bronchodilator potency but reduces tendency to lower arterial blood pressure. BRL 55834 has the potential to use as a bronchodilator.

RWJ 29009 is a highly selective ATP-sensitive potassium channel agonist. RWJ 29009 activates potassium channel in vascular smooth muscle cells, promoting potassium efflux and membrane hyperpolarization to induce coronary and peripheral vasodilation. RWJ 29009 is promising for research of cardiovascular diseases such as acute myocardial ischemia and hypertension.

LRH-0003 is an inhibitor of the Macrodomain 1 (Mac1) of nonstructural protein 3 (NSP3) from SARS-CoV-2, with an IC50 value of 1.7 μM. LRH-0003 can be used for the research antiviral infection targeting SARS-CoV-2.

GNE-5152 is an orthosteric SARM1 base-exchange (BE) inhibitor. GNE-5152 sustainably activates SARM1 at subinhibitory concentrations under mildly activating conditions, and this synergistic adverse effect increases NAD consumption, induces axon degradation and neurodegeneration and releases neurofilament-light (NfL) in cortical neurons. GNE-5152 can be used for neurodegenerative diseases research.

DMP-851 is a cyclic urea HIV protease inhibitor, with a Ki of 0.021 nM. DMP-851 shows antiviral activity against laboratory strains of HIV-l and HIV-2 as well as against primary clinical isolates derived from Zidovudine-resistant samples (A018C, E, WR 10983).

Ispinesib (SB-715992) mesylate is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.

Adavosertib-C3-NH-Boc is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for Wee1 and a PROTAC linker, which recruits E3 ligases. Adavosertib-C3-NH-Boc can be used for synthesis of PROTAC Pomalidomide-C3-adavosertib

BMS-812204 is a highly selective CB-1 receptor antagonist. BMS-812204 is promising for research of obesity and metabolic disorders.

Palbociclib-C4-Boc is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for CDK4/6 Palbociclib and a PROTAC linker, which recruits E3 ligases. Palbociclib-C4-Boc can be used for synthesis of PROTAC BSJ-03-204

E3 ligase Ligand 29-azacyclohexane-O-cyclohexane-CO is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC LRRK2 Degrader-3. PROTAC LRRK2 Degrader-3 is a potent LRRK2 PROTAC degrader with anti-neuroinflammatory activity.

Epibenzomalvin E is an isomer of Benzmalvin E. Benzomalvin E is an indoleamine 2,3-dioxygenase inhibitor.

BIEGi-1 is an EGFR inhibitor. BIEGi-1 effectively disrupts the EGFR-Rheb interaction in cells. BIEGi-1 robustly inhibits EGFR kinase activity (reduces p-Y1068-EGFR) as well as mTORC1 activation (reduces p-T389-S6K1) in EGFR-mutant cells. BIEGi-1 shows strong antiproliferative effects on EGFR-mutant PC9 and HCC827 cells with IC50 values of 17 nM and 20 nM, respectively. BIEGi-1 can be used for the study of cancers harboring EGFR mutations, such as non-small cell lung cancer (NSCLC).

Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC50 of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria.

YN14 mixture of diastereomers is the diastereomers of YN14). YN14 is a KRASG12C proteolysis targeting chimera (PROTAC). YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG). YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth.

KRASG12C ligand-1 is a PROTAC target protein ligand that can be used to synthesize the PROTAC YN14-H. YN14-H is a PROTAC degrader targeting KRASG12C and has antitumor activity.

NSC 727357 is a DNA intercalator and topoisomerase inhibitor with antitumor activity. NSC 727357 can inhibit cells proliferation and induce G1 phase arrest. NSC 727357 can be used for the research of cancer, such as melanoma.

(S)-Padsevonil is the S-enantiomer of Padsevonil).Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABAAR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models.

RO-488684 is a benzodiazepine receptor agonist. RO-488684 can be used for research on sleep and conscious sedation.

L-657743 is a highly potent, highly selective, and orally active α2-adrenoceptor antagonist. L-657743 can be used in the research of neurological diseases such as depression.

FK-664 is a leukotriene inhibitor. FK-664 enhances ventricular contractility and shortens the time to peak tension in cardiac cells. FK-664 reduces mean circulating pressure (MCP) in a canine model of heart failure. FK-664 can be used in research on cardiovascular diseases such as heart failure.

Dioxopiperidin-phthalimidine-PEG3-NBoc is a conjugate of the CRBN ligand and the linker (E3 Ligase Ligand-Linker Conjugate). Dioxopiperidin-phthalimidine-PEG3-NBoc can be used for synthesizing Bcl-xL PROTAC degrader PZ671.

Dth is a RNA aptamer-based PROTAC degrader. Dth can degrade a range of endogenous proteins (such as mCherry, p50, p65 and E2F1) by simply replacing the 3′ module on the RNA scaffold with the corresponding RNA aptamer of target protein (target aptamer).

LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide)-insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC).

ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells). ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer.

PDIC-NN dimethanesulfonate (PDIC-NS) is a STING activator with anticancer activity. PDIC-NN dimethanesulfonate promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN dimethanesulfonate triggers ROS burst and causes serious damage to mitochondria. PDIC-NN dimethanesulfonate induces cell apoptosis and inhibits DNA replication. PDIC-NN dimethanesulfonate activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response.

S7958 is a selective and orally active antagonist of the TAS2R8 bitter taste receptor, with its IC50 being 0.06 μM. S7958 only has a weak inhibitory effect on TASR8 and TAS2R39, and has no significant impact on other receptors. S7958 significantly inhibits the perception of bitterness caused by substances such as coffee and drug active ingredients (API) by selectively antagonizing the human bitter taste receptor TAS2R8. S7958 can be used in the medical field to improve the research on the bitterness of oral preparations.

Di-Val-L-dC, a prodrug of L-deoxycytidine, is a selective and specific anti-HBV agent.

dMeThPmR, a ribonucleoside derivative, is a potent and selective human nucleoside transporter 1 (hCNT1) inhibitor (Ki/sub> = 0.3-0.98 μM). dMeThPmR exhibit weak inhibitory activity on hCNT2 (IC50 = 133 μM) and hCNT3 (Ki = 32.7 μM). dMeThPmR can protect cells from the toxicity of nucleoside drugs. dMeThPmR can be used for the research of cancer.

BEA 005 is an antivirus agent. BEA 005 can block early systemic and mucosal infections with SIV and HIV-2.